Sutro Biopharma (STRO) Common Equity (2016 - 2025)

Sutro Biopharma has disclosed Common Equity across 10 years of filings, most recently posting -$132.5 million for Q4 2025.

• Common Equity for Q4 2025 came in at -$132.5 million, down 396.97% year-over-year; the trailing twelve-month figure through Dec 2025 was -$132.5 million (down 396.97% YoY), and the FY2025 annual result was -$132.5 million, down 396.97% from the prior year.
• Common Equity came in at -$132.5 million for Q4 2025 at Sutro Biopharma, down from -$87.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $307.5 million in Q2 2021 to a low of -$132.5 million in Q4 2025.
• The 5-year median for Common Equity is $153.4 million (2023), against an average of $137.9 million.
• Across the five-year window, Common Equity soared 274.41% in 2021 and slumped 396.97% in 2025, its largest moves.
• Sutro Biopharma's Common Equity stood at $252.6 million in 2021, then declined by 14.06% to $217.0 million in 2022, then tumbled by 31.05% to $149.6 million in 2023, then slumped by 70.2% to $44.6 million in 2024, then tumbled by 396.97% to -$132.5 million in 2025.
• The last three Common Equity figures came in at -$132.5 million (Q4 2025), -$87.3 million (Q3 2025), and -$32.1 million (Q2 2025), per Business Quant data.